News

AVI BioPharma has presented initial efficacy data from the ongoing phase 1b/2 clinical trial of AVI-4658 for the systemic treatment of patients with Duchenne muscular dystrophy (DMD). Patients

Intermountain Healthcare has entered into a multi-year agreement with Craneware to advance standardization of its charge description master (CDM) management process, with Craneware’s chargemaster automation solution. Intermountain Healthcare

The Dow Chemical Company (Dow) has announced a new Pacific leadership team in the Asia Pacific region. Jim McIlvenny has been named senior vice president of performance products;

Mitsui Chemicals (MCI), Tohcello and Mitsui Chemicals Fabro, (Fabro) have entered into a Fundamental Agreement to study integration of film/sheet businesses of the three companies. Under the Fundamental

Air Liquide, through its subsidiary Shanghai Chemical Industry Park Industrial Gases (SCIPIG), has signed a new 15-year industrial gases contract with Bayer Polyurethanes (Shanghai)(BPUS). Reportedly, SCIPIG is expected

The European Medicines Agency (EMEA) has granted Cell Therapeutics’ (CTI) Pixantrone, orphan drug designation for the treatment of diffuse large b-cell lymphoma (DLBCL). CTI expects to file the

Soligenix, formerly known as Dor BioPharma, has initiated a phase 1/2 clinical trial evaluating SGX201, a time-release formulation of oral beclomethasone 17,21-dipropionate (oral BDP), for the prevention of

The FDA has extended the action date for its review of Cephalon’s supplemental New Drug Application (sNDA) for Nuvigil (armodafinil) tablets [C-IV], to March 29, 2010. The sNDA

Actelion has said that the first phase III study with Almorexant (Restora 1) has met its primary endpoint – superiority of the dual orexin receptor antagonist Almorexant compared